News

The Phase II study is a two-arm, randomized, controlled 100-patient trial of first-line treatment of metastatic colorectal cancer. The objective of the Phase II trial is to compare

NB S101, a dual acting bone agent, has a demonstrated ability to decrease resorption of bone while maintaining formation of new bone. The drug has been formulated as

Dr Tellier joins MacroGenics after a 20 year career in commercial development at Novartis. Since February 2007, he served as chairman and CEO of Novartis Pharma France and

The Contrave clinical development program includes four Phase III clinical trials evaluating a variety of obesity and metabolic-related outcome measures. Orexigen previously announced that enrollment was completed in

ClariVein is a percutaneous, 2 2/3 Fr (0.035″) catheter, containing a rotating wire driven by a motor, that enhances fluid dispersion in the treatment area. John Marano, co-founder,

The Dilon system is a high-resolution gamma camera that enables molecular imaging of the breast and other small organs for early cancer detection. Robert Moussa, chairman and CEO

The company intends to close on approximately $1.5 million immediately upon AMEX approval and customary closing conditions, with the balance at the company’s option and subject to stockholder

The new test uses advanced genomics-based technology to help physicians determine a tumor’s origin in order to optimize cancer-specific treatment. The study will evaluate the test’s ability to

The company also reported that the Center for Biologics Evaluation and Research (CBER), a division of the FDA, has approved the synopsis to conduct a Phase I clinical